CureSCi Metadata Catalog—finding and harmonizing studies for secondary analysis of hydroxyurea use for sickle cell disease
Preprint
Abstract
Objectives Sickle cell disease (SCD) is a rare group of inherited red blood cell disorders that affect hemoglobin, resulting in serious multi-system complications. The limited number of patients available to participate in research studies can inhibit investigating sophisticated relationships. Secondary analysis is a research method that involves using existing data to answer new research questions. Data harmonization enables secondary analysis by combining data across studies, especially helpful for rare disease research where individual studies may be small. The National Heart, Lung, and Blood Institute Cure Sickle Cell Initiative (CureSCi) Metadata Catalog is a web-based tool to identify SCD study datasets for conducting data harmonization and secondary analysis. We present a proof-of-concept secondary analysis to explore factors associated with discontinuation of hydroxyurea, a safe and effective first line SCD therapy, to illustrate the utility of the CureSCi Metadata Catalog to expedite and enable more robust SCD research. Methods We performed secondary analysis of SCD studies using a multi-step workflow: develop research questions, identify study datasets, identify variables of interest, harmonize variables, and establish an analysis method. A harmonized dataset consisting of eight predictor variables across five studies was created. Secondary analysis involved a generalized linear model was employed to identify factors that significantly impact hydroxyurea discontinuation. Results The CureSCi Metadata Catalog provided a platform to efficiently find relevant studies and design a harmonization strategy to prepare data for secondary analysis. Multivariate analysis of the harmonized identified that patients who are older, are female, had a history of blood transfusion therapy, had episodes of acute chest syndrome, and had the SC sickle cell genotype are more likely to stop hydroxyurea treatment. Conclusion This secondary analysis provides a template for how the CureSCi Metadata Catalog expedites dataset discovery of sickle cell studies for identifying relationships between variables or validating existing findings.Keywords
This publication has 21 references indexed in Scilit:
- Understanding Sickle cell disease: Causes, symptoms, and treatment optionsMedicine, 2023
- Hydroxyurea (hydroxycarbamide) for sickle cell diseaseCochrane Database of Systematic Reviews, 2022
- Sickle Cell DiseaseJAMA, 2022
- Pregnancy outcomes with hydroxyurea use in women with sickle cell diseaseAmerican Journal of Hematology, 2022
- Oxidative stress assessment in sickle cell anemia patients treated with hydroxyureaAnnals of Hematology, 2020
- Hydroxyurea use in young infants with sickle cell diseasePediatric Blood & Cancer, 2019
- Sickle cell diseaseNature Reviews Disease Primers, 2018
- Adult Sickle Cell Quality-of-Life Measurement Information System (ASCQ-Me)The Clinical Journal of Pain, 2014
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- Hydroxyurea in sickle cell disease—A study of clinico-pharmacological efficacy in the Indian haplotypeBlood Cells, Molecules, and Diseases, 2009